Patents by Inventor Rita M. Steeves

Rita M. Steeves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Integrin Immunoconjugates, Methods and Uses
    Publication number: 20140093523
    Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
    Type: Application
    Filed: December 4, 2013
    Publication date: April 3, 2014
    Applicants: Immunogen, Inc., Janssen Biotech, Inc.
    Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
  • Anti-integrin immunoconjugates, methods and uses
    Patent number: 8603483
    Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: December 10, 2013
    Assignees: Janssen Biotech, Inc., Immunogen, Inc.
    Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
  • METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES
    Publication number: 20120226025
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Applicant: IMMUNOGEN, INC.
    Inventors: Ravi V.J. CHARI, Wayne WIDDISON, Rita M. STEEVES, Walter A. BLATTLER
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
    Patent number: 8198417
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 12, 2012
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
    Patent number: 8163888
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 24, 2012
    Assignee: Immunogen, Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
    Patent number: 8088387
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: January 3, 2012
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blättler
  • Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
    Patent number: 7989598
    Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: August 2, 2011
    Assignee: Immunogen Inc.
    Inventors: Rita M. Steeves, Ravi V. J. Chari, Walter A. Blattler